Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma, Renal Cell Metastasis: early-phase trial registry
1 of 2 indexed Carcinoma, Renal Cell Metastasis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Carcinoma, Renal Cell Metastasis: 2 US clinical trials tracked, 1 recruiting.
Carcinoma, Renal Cell Metastasis is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 2 of these trials.
Enrollment posture brief
Registry condition carcinoma-renal-cell-metastasis
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Carcinoma, Renal Cell Metastasis lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma, Renal Cell Metastasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma, Renal Cell Metastasis is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
NCT07227415
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Pfizer
NCT00137423
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma, Renal Cell Metastasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma, Renal Cell Metastasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma, Renal Cell Metastasis page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Carcinoma, Renal Cell Metastasis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Carcinoma, Renal Cell Metastasis trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma, Renal Cell Metastasis condition card totals 2 registered trials; most-linked intervention SU011248 (sunitinib); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.